A systematic review of the safety of topical therapies for atopic dermatitis

J. Callen, S. Chamlin, L. F. Eichenfield, C. Ellis, M. Girardi, M. Goldfarb, Jon Hanifin, P. Lee, D. Margolis, A. S. Paller, D. Piacquadio, W. Peterson, K. Kaulback, M (Brian) Fennerty, B. U. Wintroub

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

Background: The safety of topical therapies for atopic dermatitis (AD), a common and morbid disease, has recently been the focus of increased scrutiny, adding confusion as how best to manage these patients. Objectives: The objective of these systematic reviews was to determine the safety of topical therapies for AD. Methods: Databases searched included: OVID Medline, Medline In-Process and Other Non-Indexed Citations, Embase, and the Cochrane Central Register of Controlled Trials. In addition to the articles identified by this search, investigators were also referred to a list of links (most recently updated 25 September 2005) to recent Food and Drug Administration (FDA) studies, reports and meetings regarding the topical calcineurin inhibitors for further potential references. Only fully published papers available in English and data obtained from FDA sites were included. Furthermore, the criteria for inclusion and exclusion for each systematic review were further evaluated at a meeting of all of the content and evidence-based medicine experts participating in this process and alteration of the inclusion criteria was done at that time when it was felt necessary to avoid inclusion of lower-quality data in the review. Qualitative review of the abstracted data was performed and reviewed at a meeting of all of the content and evidence-based medicine experts. Results: While systemic exposure to these topical agents does occur, physiological changes appear to be uncommon and systemic complications rare and have only been found with use of topical corticosteroids. Conclusions: Based on the data that are available the overall safety of AD therapies appears to be good with the only documented systemic side-effects of therapy those occasionally seen with use of topical corticosteroids.

Original languageEnglish (US)
Pages (from-to)203-221
Number of pages19
JournalBritish Journal of Dermatology
Volume156
Issue number2
DOIs
StatePublished - Feb 2007

Fingerprint

Atopic Dermatitis
Safety
Evidence-Based Medicine
United States Food and Drug Administration
Adrenal Cortex Hormones
Therapeutics
Research Personnel
Databases

Keywords

  • Atopic dermatitis
  • Calcineurin inhibitors
  • Safety
  • Steroids

ASJC Scopus subject areas

  • Dermatology

Cite this

Callen, J., Chamlin, S., Eichenfield, L. F., Ellis, C., Girardi, M., Goldfarb, M., ... Wintroub, B. U. (2007). A systematic review of the safety of topical therapies for atopic dermatitis. British Journal of Dermatology, 156(2), 203-221. https://doi.org/10.1111/j.1365-2133.2006.07538.x

A systematic review of the safety of topical therapies for atopic dermatitis. / Callen, J.; Chamlin, S.; Eichenfield, L. F.; Ellis, C.; Girardi, M.; Goldfarb, M.; Hanifin, Jon; Lee, P.; Margolis, D.; Paller, A. S.; Piacquadio, D.; Peterson, W.; Kaulback, K.; Fennerty, M (Brian); Wintroub, B. U.

In: British Journal of Dermatology, Vol. 156, No. 2, 02.2007, p. 203-221.

Research output: Contribution to journalArticle

Callen, J, Chamlin, S, Eichenfield, LF, Ellis, C, Girardi, M, Goldfarb, M, Hanifin, J, Lee, P, Margolis, D, Paller, AS, Piacquadio, D, Peterson, W, Kaulback, K, Fennerty, MB & Wintroub, BU 2007, 'A systematic review of the safety of topical therapies for atopic dermatitis', British Journal of Dermatology, vol. 156, no. 2, pp. 203-221. https://doi.org/10.1111/j.1365-2133.2006.07538.x
Callen J, Chamlin S, Eichenfield LF, Ellis C, Girardi M, Goldfarb M et al. A systematic review of the safety of topical therapies for atopic dermatitis. British Journal of Dermatology. 2007 Feb;156(2):203-221. https://doi.org/10.1111/j.1365-2133.2006.07538.x
Callen, J. ; Chamlin, S. ; Eichenfield, L. F. ; Ellis, C. ; Girardi, M. ; Goldfarb, M. ; Hanifin, Jon ; Lee, P. ; Margolis, D. ; Paller, A. S. ; Piacquadio, D. ; Peterson, W. ; Kaulback, K. ; Fennerty, M (Brian) ; Wintroub, B. U. / A systematic review of the safety of topical therapies for atopic dermatitis. In: British Journal of Dermatology. 2007 ; Vol. 156, No. 2. pp. 203-221.
@article{34a546c9fef944fc83a875c3fe80b61f,
title = "A systematic review of the safety of topical therapies for atopic dermatitis",
abstract = "Background: The safety of topical therapies for atopic dermatitis (AD), a common and morbid disease, has recently been the focus of increased scrutiny, adding confusion as how best to manage these patients. Objectives: The objective of these systematic reviews was to determine the safety of topical therapies for AD. Methods: Databases searched included: OVID Medline, Medline In-Process and Other Non-Indexed Citations, Embase, and the Cochrane Central Register of Controlled Trials. In addition to the articles identified by this search, investigators were also referred to a list of links (most recently updated 25 September 2005) to recent Food and Drug Administration (FDA) studies, reports and meetings regarding the topical calcineurin inhibitors for further potential references. Only fully published papers available in English and data obtained from FDA sites were included. Furthermore, the criteria for inclusion and exclusion for each systematic review were further evaluated at a meeting of all of the content and evidence-based medicine experts participating in this process and alteration of the inclusion criteria was done at that time when it was felt necessary to avoid inclusion of lower-quality data in the review. Qualitative review of the abstracted data was performed and reviewed at a meeting of all of the content and evidence-based medicine experts. Results: While systemic exposure to these topical agents does occur, physiological changes appear to be uncommon and systemic complications rare and have only been found with use of topical corticosteroids. Conclusions: Based on the data that are available the overall safety of AD therapies appears to be good with the only documented systemic side-effects of therapy those occasionally seen with use of topical corticosteroids.",
keywords = "Atopic dermatitis, Calcineurin inhibitors, Safety, Steroids",
author = "J. Callen and S. Chamlin and Eichenfield, {L. F.} and C. Ellis and M. Girardi and M. Goldfarb and Jon Hanifin and P. Lee and D. Margolis and Paller, {A. S.} and D. Piacquadio and W. Peterson and K. Kaulback and Fennerty, {M (Brian)} and Wintroub, {B. U.}",
year = "2007",
month = "2",
doi = "10.1111/j.1365-2133.2006.07538.x",
language = "English (US)",
volume = "156",
pages = "203--221",
journal = "British Journal of Dermatology",
issn = "0007-0963",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - A systematic review of the safety of topical therapies for atopic dermatitis

AU - Callen, J.

AU - Chamlin, S.

AU - Eichenfield, L. F.

AU - Ellis, C.

AU - Girardi, M.

AU - Goldfarb, M.

AU - Hanifin, Jon

AU - Lee, P.

AU - Margolis, D.

AU - Paller, A. S.

AU - Piacquadio, D.

AU - Peterson, W.

AU - Kaulback, K.

AU - Fennerty, M (Brian)

AU - Wintroub, B. U.

PY - 2007/2

Y1 - 2007/2

N2 - Background: The safety of topical therapies for atopic dermatitis (AD), a common and morbid disease, has recently been the focus of increased scrutiny, adding confusion as how best to manage these patients. Objectives: The objective of these systematic reviews was to determine the safety of topical therapies for AD. Methods: Databases searched included: OVID Medline, Medline In-Process and Other Non-Indexed Citations, Embase, and the Cochrane Central Register of Controlled Trials. In addition to the articles identified by this search, investigators were also referred to a list of links (most recently updated 25 September 2005) to recent Food and Drug Administration (FDA) studies, reports and meetings regarding the topical calcineurin inhibitors for further potential references. Only fully published papers available in English and data obtained from FDA sites were included. Furthermore, the criteria for inclusion and exclusion for each systematic review were further evaluated at a meeting of all of the content and evidence-based medicine experts participating in this process and alteration of the inclusion criteria was done at that time when it was felt necessary to avoid inclusion of lower-quality data in the review. Qualitative review of the abstracted data was performed and reviewed at a meeting of all of the content and evidence-based medicine experts. Results: While systemic exposure to these topical agents does occur, physiological changes appear to be uncommon and systemic complications rare and have only been found with use of topical corticosteroids. Conclusions: Based on the data that are available the overall safety of AD therapies appears to be good with the only documented systemic side-effects of therapy those occasionally seen with use of topical corticosteroids.

AB - Background: The safety of topical therapies for atopic dermatitis (AD), a common and morbid disease, has recently been the focus of increased scrutiny, adding confusion as how best to manage these patients. Objectives: The objective of these systematic reviews was to determine the safety of topical therapies for AD. Methods: Databases searched included: OVID Medline, Medline In-Process and Other Non-Indexed Citations, Embase, and the Cochrane Central Register of Controlled Trials. In addition to the articles identified by this search, investigators were also referred to a list of links (most recently updated 25 September 2005) to recent Food and Drug Administration (FDA) studies, reports and meetings regarding the topical calcineurin inhibitors for further potential references. Only fully published papers available in English and data obtained from FDA sites were included. Furthermore, the criteria for inclusion and exclusion for each systematic review were further evaluated at a meeting of all of the content and evidence-based medicine experts participating in this process and alteration of the inclusion criteria was done at that time when it was felt necessary to avoid inclusion of lower-quality data in the review. Qualitative review of the abstracted data was performed and reviewed at a meeting of all of the content and evidence-based medicine experts. Results: While systemic exposure to these topical agents does occur, physiological changes appear to be uncommon and systemic complications rare and have only been found with use of topical corticosteroids. Conclusions: Based on the data that are available the overall safety of AD therapies appears to be good with the only documented systemic side-effects of therapy those occasionally seen with use of topical corticosteroids.

KW - Atopic dermatitis

KW - Calcineurin inhibitors

KW - Safety

KW - Steroids

UR - http://www.scopus.com/inward/record.url?scp=33846242915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846242915&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2133.2006.07538.x

DO - 10.1111/j.1365-2133.2006.07538.x

M3 - Article

C2 - 17223859

AN - SCOPUS:33846242915

VL - 156

SP - 203

EP - 221

JO - British Journal of Dermatology

JF - British Journal of Dermatology

SN - 0007-0963

IS - 2

ER -